Session XX: Colorectal Cancer: Presentation of selected abstracts
Phase II study evaluating trifluridine/tipiracil+bevacizumab and capecitabine+bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): results of the primary analysis
Eric Van Cutsem, et al., O-022 SLIDES
The authors of the study conclude that "The promising activity of TT-B observed in the C-TASK Force trial was confirmed in the TASCO1 phase 2 trial in 1st line mCRC patients non-eligible for intensive therapy. The opportunity to conduct a global confirmatory phase 3 trial versus C-B is currently being evaluated."
See the statement from Eric Van Cutsem about the clinical significance of Trifluridine/Tipiracil below
FOLFOX/Bevacizumab +/- Irinotecan in advanced colorectal cancer (CHARTA): long-term outcome
Hans-Joachim Schmoll, et al., O-023
The authors of the study conclude that "After 12 further months of follow-up with a median of 38 with a maximum of 7 years. All data for PFS and OS are mature and ready for final evaluation, including clinical and molecular subgroup and multivariate analyses as well data on reinduction and salvage treatments. Translational research is ongoing. The final clinical data will be available at the meeting."
mFOLFOXIRI + Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer m(CRC): a randomized phase II VOLFI trial of the AIO (AIO- KRK0109)
Michael Geissler, et al., O-024
The authors of the study conclude that " mFOLFOXIRI plus panitumumab results in significantly higher response rates compared to FOLFOXIRI in RAS wild-type mCRC. Strong effectivity was observed also in right sided and BRAF mutated CRC. High secondary resection rates could be achieved. Although toxicity (treatment related SAEs) was increased, QL reporting was similar in both arms. Final PFS, AEs, and dosing data will be presented at the meeting. "
The authors of the study conclude that "Among MSI-High gastrointestinal cancers, CRC exhibited the highest TMB level, and left-sided tumors exhibited higher TMB than right-sided tumors. MSH2 and/or MSH6 alterations were associated with a significantly higher TMB than MLH1/PMS2 alterations across all gastrointestinal cancer types. Additional analysis to assess the correlation between specific MMR gene alterations and response to checkpoint inhibitors is underway."
The authors of the study conclude that "The level of total cfDNA in plasma has prognostic value in patients with mCRC prior to first-line oxaliplatin-based chemotherapy."
BEACON CRC Study Safety Lead-in: Assessment of the BRAF Inhibitor Encorafenib + MEK Inhibitor Binimetinib + Anti–Epidermal Growth Factor Receptor Antibody Cetuximab for BRAFV600E Metastatic Colorectal Cancer
Eric Van Cutsem, et al., O-027
The authors of the study conclude that "The ENCO + BINI + CETUX triplet combination was well tolerated, with AEs consistent with known toxicities of BRAF, MEK, and EGFR inhibitors. Efficacy outcomes showed substantial improvements over historical data in patients with BRAFV600E mCRC, with PFS exceeding OS achieved with current standards of care. The phase 3 portion of the BEACON CRC trial has been initiated, with enrollment ongoing."
Long-term effect of peripheral sensory neuropathy (PSN) of 3 or 6 months oxaliplatin-based adjuvant chemotherapy for stage III colon cancer: ACHIEVE as part of the IDEA collaboration
Shintaro Takeuchi, et al., O-028
The authors of the study conclude that "In the 3-month arm, grade 2 or greater PSN was not observed at 3 years after the treatment. The frequency of grade 1 PSN lasting for three years was decreased to about a half (21.5% -> 9.7%) in the 3rd month as compared to the 6-month arm. The 3 months oxaliplatin-based adjuvant chemotherapy can bring a substantial reduction in long-term neuropathy and potential improvement in quality of life to patients without undermining the efficacy."